Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: Clin Cancer Res. 2013 Apr 2;19(11):2984–2994. doi: 10.1158/1078-0432.CCR-12-2008

Figure 6.

Figure 6

A. Antitumor activity of the IGF-ligand binding antibody (MED-573) or IGF-1 receptor-binding antibody (CP01-B02) alone or in combination (MEDI + CP). Antibodies were administered twice weekly at 30 mg/kg (MEDI-573), or 20 mg/kg (CP01-B-02) for a planned treatmen of 6 weeks. Treatment was initiated when tumors exceeded 100 mm3. B. Tumors were harvested at ‘event’ (4-fold tumor volume at treatment initiation), and stained for CD34 to determine tumor microvessels, and Ki67 to assess proliferation.